Please enable JS


Investors & Media

Viamet is a pharmaceutical company focused on the discovery, development and commercialization of novel therapies based on our proprietary metalloenzyme chemistry and biology technology, which we call MIDAS. We are utilizing our technology to design novel drugs that we expect to have greater selectivity, improved potency and superior therapeutic index compared to currently available metalloenzyme inhibitors. We believe that our technology is applicable to a broad range of metalloenzyme targets across many therapeutic classes.


Public Relations:
MacDougall Biomedical Communications
Stefanie Tuck
(781) 235-3060

Neil Moore
VP, Operations
Viamet Pharmaceuticals, Inc.
(919) 467-8539